我们旨在评估指南委员会作者和用于支持欧洲心脏病学会(ESC)指南的研究研究作者之间财务利益冲突的频率和性质。
我们评估了撰写五个关键ESC临床实践指南(CPG)的医生的竞争利益:瓣膜性心脏病(VHD),心房颤动(AF),心包疾病(PD),心力衰竭(HF)和心肌血运重建(IHD)。此外,我们检查了建议中引用的与药物相关的研究的资金来源.如果一项研究是由工业界赞助的,我们对所有作者的披露进行了审查,以评估与研究资助者是否存在经济利益冲突.
总共,在五项指南中有603项建议(PD112、VHD111、HF169、IHD97和AF114),其中,271(45%(PD26,VHD23,HF72,IHD84和AF66))与药物相关。至少80%的指南委员会作者,除了警署指引,有相关的财务利益冲突,最常见的是直接个人付款(68%-82%)。在整个指南中,行业对研究的支持从5%(PD)到65%(IHD)不等。如果一项研究是由行业资助的,作者经常(55-90%)与行业赞助商发生冲突。
撰写临床指南的大多数医生都存在相关的经济利益冲突。此外,行业赞助研究频繁,作者经常与研究资助者发生冲突。我们建议撰写临床指南的医生应避免此类财务利益冲突,以保持临床指南的科学完整性和独立性。
We aimed to assess the frequency and nature of financial conflicts of interest among both the
guideline committee authors and the authors of research studies used to support the European Society of Cardiology (ESC)
guidelines.
We evaluated the competing interests of the doctors that write five of the key ESC clinical practice guidelines (CPG): valvular heart disease (VHD), atrial fibrillation (AF), pericardial diseases (PD), heart failure (HF) and myocardial revascularisation (IHD). In addition, we examined the funding sources of studies cited in the recommendations that were related to pharmaceutical agents. If a study was sponsored by industry, the disclosures of all authors were reviewed to assess whether there was a financial conflict of interest with the study funder.
In total, there were 603 recommendations (PD 112, VHD 111, HF 169, IHD 97 and AF 114) across the five guidelines, of which, 271 (45% (PD 26, VHD 23, HF 72, IHD 84 and AF 66)) related to pharmaceutical agents. At least 80% of
guideline committee authors, except for the PD
guidelines, had a relevant financial conflict of interest, with the most frequent being a direct personal payment (68-82%). Industry support for studies varied across the
guidelines from 5% (PD) to 65% (IHD). If a study was funded by industry, authors were frequently (55-90%) conflicted with the industry sponsor.
The majority of the doctors that write clinical guidelines have a relevant financial conflict of interest. In addition, industry sponsorship of studies is frequent, and authors are often conflicted with the study funder. We propose that physicians that write clinical guidelines should be free of such financial conflicts of interest to maintain scientific integrity and independence in the clinical
guidelines.